The epigenetics of tumour initiation: Cancer stem cells and their chromatin

Current Opinion in Genetics and Development

Volumn 36, Issue , 2016, Pages 8-15

  Avgustinova, Alexandra ^a   Benitah, Salvador Aznar ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; POLYCOMB REPRESSIVE COMPLEX 2; CHROMATIN;

CANCER STEM CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA REPAIR; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENOMIC INSTABILITY; HISTONE MODIFICATION; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRC2 GENE; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION; CELL TRANSFORMATION; GENETIC EPIGENESIS; GENETICS; NEOPLASM;

CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; DNA REPAIR; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84957800593     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2016.01.003     Document Type: Review

References (76)

1. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013, 153:38-55.
2. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell 2012, 22:9-20.
3. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells - what challenges do they pose?. Nat Rev Drug Discov 2014, 13:497-512.
4. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
5. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., Maitland N.J., Collins A.T. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004, 117:3539-3545.
6. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
7. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
8. Lee A., Kessler J.D., Read T.A., Kaiser C., Corbeil D., Huttner W.B., Johnson J.E., Wechsler-Reya R.J. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 2005, 8:723-729.
9. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011, 108:7950-7955.
10. Chaffer C.L., Marjanovic N.D., Lee T., Bell G., Kleer C.G., Reinhardt F., D'Alessio A.C., Young R.A., Weinberg R.A. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154:61-74.
11. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011, 108:1397-1402.
12. Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., Lander E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
13. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., Zabierowski S.E., Brafford P.A., Vultur A., Basu D., Gimotty P., Vogt T., Herlyn M. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
14. He K., Xu T., Goldkorn A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther 2011, 10:938-948.
15. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
16. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
17. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
18. Greaves M. Evolutionary determinants of cancer. Cancer Discov 2015, 5:806-820.
19. Tessarz P., Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol 2014, 15:703-708.
20. Rinaldi L., Benitah S.A. Epigenetic regulation of adult stem cell function. FEBS J 2015, 282:1589-1604.
21. Shukla S., Meeran S.M. Epigenetics of cancer stem cells: pathways and therapeutics. Biochim Biophys Acta 2014, 1840:3494-3502.
22. Kouzarides T. SnapShot: histone-modifying enzymes. Cell 2007, 128:802.
23. Morgan M.A., Shilatifard A. Chromatin signatures of cancer. Genes Dev 2015, 29:238-249.
24. Yamazaki J., Estecio M.R., Lu Y., Long H., Malouf G.G., Graber D., Huo Y., Ramagli L., Liang S., Kornblau S.M., et al. The epigenome of AML stem and progenitor cells. Epigenetics 2013, 8:92-104.
25. Aiden A.P., Rivera M.N., Rheinbay E., Ku M., Coffman E.J., Truong T.T., Vargas S.O., Lander E.S., Haber D.A., Bernstein B.E. Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell 2010, 6:591-602.
26. Lin B., Lee H., Yoon J.G., Madan A., Wayner E., Tonning S., Hothi P., Schroeder B., Ulasov I., Foltz G., et al. Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene. Oncotarget 2015, 6:5369-5381.
27. Trowbridge J.J., Sinha A.U., Zhu N., Li M., Armstrong S.A., Orkin S.H. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012, 26:344-349.
28. Easwaran H., Johnstone S.E., Van Neste L., Ohm J., Mosbruger T., Wang Q., Aryee M.J., Joyce P., Ahuja N., Weisenberger D., et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012, 22:837-849.
29. Lewis P.W., Muller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
30. Schwartzentruber J., Korshunov A., Liu X.Y., Jones D.T., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.A., Tonjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
31. Wu G., Diaz A.K., Paugh B.S., Rankin S.L., Ju B., Li Y., Zhu X., Qu C., Chen X., Zhang J., et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014, 46:444-450.
32. Takawa M., Masuda K., Kunizaki M., Daigo Y., Takagi K., Iwai Y., Cho H.S., Toyokawa G., Yamane Y., Maejima K., et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011, 102:1298-1305.
33. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003, 100:11606-11611.
34. Holm K., Grabau D., Lovgren K., Aradottir S., Gruvberger-Saal S., Howlin J., Saal L.H., Ethier S.P., Bendahl P.O., Stal O., et al. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012, 6:494-506.
35. Simon C., Chagraoui J., Krosl J., Gendron P., Wilhelm B., Lemieux S., Boucher G., Chagnon P., Drouin S., Lambert R., et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012, 26:651-656.
36. Ntziachristos P., Tsirigos A., Welstead G.G., Trimarchi T., Bakogianni S., Xu L., Loizou E., Holmfeldt L., Strikoudis A., King B., et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 2014, 514:513-517.
37. Laugesen A., Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 2014, 14:735-751.
38. Yu C.C., Lo W.L., Chen Y.W., Huang P.I., Hsu H.S., Tseng L.M., Hung S.C., Kao S.Y., Chang C.J., Chiou S.H. Bmi-regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol 2011, 2011.
39. West A.C., Johnstone R.W. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014, 124:30-39.
40. Santoro F., Botrugno O.A., Dal Zuffo R., Pallavicini I., Matthews G.M., Cluse L., Barozzi I., Senese S., Fornasari L., Moretti S., et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 2013, 121:3459-3468.
41. Schuster-Bockler B., Lehner B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012, 488:504-507.
42. Polak P., Karlic R., Koren A., Thurman R., Sandstrom R., Lawrence M.S., Reynolds A., Rynes E., Vlahovicek K., Stamatoyannopoulos J.A., et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 2015, 518:360-364.
43. Peters A.H., O'Carroll D., Scherthan H., Mechtler K., Sauer S., Schofer C., Weipoltshammer K., Pagani M., Lachner M., Kohlmaier A., et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001, 107:323-337.
44. Kondo Y., Shen L., Ahmed S., Boumber Y., Sekido Y., Haddad B.R., Issa J.P. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS ONE 2008, 3:e2037.
45. Black J.C., Manning A.L., Van Rechem C., Kim J., Ladd B., Cho J., Pineda C.M., Murphy N., Daniels D.L., Montagna C., et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 2013, 154:541-555.
46. Vissers J.H., van Lohuizen M., Citterio E. The emerging role of Polycomb repressors in the response to DNA damage. J Cell Sci 2012, 125:3939-3948.
47. Shanbhag N.M., Rafalska-Metcalf I.U., Balane-Bolivar C., Janicki S.M., Greenberg R.A. ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. Cell 2010, 141:970-981.
48. Kakarougkas A., Ismail A., Chambers A.L., Riballo E., Herbert A.D., Kunzel J., Lobrich M., Jeggo P.A., Downs J.A. Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin. Mol Cell 2014, 55:723-732.
49. Kalousi A., Hoffbeck A.S., Selemenakis P.N., Pinder J., Savage K.I., Khanna K.K., Brino L., Dellaire G., Gorgoulis V.G., Soutoglou E. The nuclear oncogene SET controls DNA repair by KAP1 and HP1 retention to chromatin. Cell Rep 2015, 11:149-163.
50. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
51. Suva M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
52. Christophorou M.A., Castelo-Branco G., Halley-Stott R.P., Oliveira C.S., Loos R., Radzisheuskaya A., Mowen K.A., Bertone P., Silva J.C., Zernicka-Goetz M., et al. Citrullination regulates pluripotency and histone H1 binding to chromatin. Nature 2014, 507:104-108.
53. Onder T.T., Kara N., Cherry A., Sinha A.U., Zhu N., Bernt K.M., Cahan P., Marcarci B.O., Unternaehrer J., Gupta P.B., et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012, 483:598-602.
54. Chen J., Liu H., Liu J., Qi J., Wei B., Yang J., Liang H., Chen Y., Chen J., Wu Y., et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet 2013, 45:34-42.
55. He J., Nguyen A.T., Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 2011, 117:3869-3880.
56. Rompolas P., Deschene E.R., Zito G., Gonzalez D.G., Saotome I., Haberman A.M., Greco V. Live imaging of stem cell and progeny behaviour in physiological hair-follicle regeneration. Nature 2012, 487:496-499.
57. van Es J.H., Sato T., van de Wetering M., Lyubimova A., Nee A.N., Gregorieff A., Sasaki N., Zeinstra L., van den Born M., Korving J., et al. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. Nat Cell Biol 2012, 14:1099-1104.
58. Tata P.R., Mou H., Pardo-Saganta A., Zhao R., Prabhu M., Law B.M., Vinarsky V., Cho J.L., Breton S., Sahay A., et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 2013, 503:218-223.
59. Yanger K., Knigin D., Zong Y., Maggs L., Gu G., Akiyama H., Pikarsky E., Stanger B.Z. Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. Cell Stem Cell 2014, 15:340-349.
60. Tetteh P.W., Farin H.F., Clevers H. Plasticity within stem cell hierarchies in mammalian epithelia. Trends Cell Biol 2015, 25:100-108.
61. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
62. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
63. Wang Z., Ali S., Banerjee S., Bao B., Li Y., Azmi A.S., Korc M., Sarkar F.H. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol 2013, 228:556-562.
64. Tam W.L., Weinberg R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013, 19:1438-1449.
65. Herranz N., Pasini D., Diaz V.M., Franci C., Gutierrez A., Dave N., Escriva M., Hernandez-Munoz I., Di Croce L., Helin K., et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008, 28:4772-4781.
66. Tiwari N., Tiwari V.K., Waldmeier L., Balwierz P.J., Arnold P., Pachkov M., Meyer-Schaller N., Schubeler D., van Nimwegen E., Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23:768-783.
67. Dong C., Wu Y., Yao J., Wang Y., Yu Y., Rychahou P.G., Evers B.M., Zhou B.P. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 2012, 122:1469-1486.
68. Dong C., Wu Y., Wang Y., Wang C., Kang T., Rychahou P.G., Chi Y.I., Evers B.M., Zhou B.P. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 2013, 32:1351-1362.
69. Beck B., Lapouge G., Rorive S., Drogat B., Desaedelaere K., Delafaille S., Dubois C., Salmon I., Willekens K., Marine J.C., et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 2015, 16:67-79.
70. Schmidt J.M., Panzilius E., Bartsch H.S., Irmler M., Beckers J., Kari V., Linnemann J.R., Dragoi D., Hirschi B., Kloos U.J., et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep 2015, 10:131-139.
71. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014, 13:673-691.
72. Seton-Rogers S. Therapeutics: delving deeper into resistance. Nat Rev Cancer 2014, 14:7.
73. Filippakopoulos P., Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014, 13:337-356.
74. Hojfeldt J.W., Agger K., Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013, 12:917-930.
75. Azad N., Zahnow C.A., Rudin C.M., Baylin S.B. The future of epigenetic therapy in solid tumours - lessons from the past. Nat Rev Clin Oncol 2013, 10:256-266.
76. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11:726-734.